62 results
Page 3 of 4
8-K
EX-1.1
thc6 wsttq5
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
8-K
EX-1.2
jzrr 1yvalnopfr8
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
DEFA14A
tii8ge6l1pfww2bir
24 Apr 19
Additional proxy soliciting materials
5:30pm
8-K
EX-1.1
4oh k7yf1a
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
8-K
EX-1.2
4760wydaw6e
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
8-K
EX-99.1
dzds 4twjrxh
17 Dec 18
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
8:05am
8-K
EX-99.1
2rxepdvay5n p7j
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
EX-99.1
d540uy
6 Aug 18
Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome
7:16am
S-3
EX-1.2
9j2dbmni3 2y
1 Jun 18
Shelf registration
5:14pm
10-K
olt5rk tiy
29 Mar 18
Annual report
12:00am